Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
Limited agents are optional after standard first and second line treatment for mCRC.
Nowadays, cancer therapy has entered the era of immunotherapy. The approved cancer therapies
include pembrolizumab and nivolumab, but only for MSI-H patients. 95% of non MSI-H / dMMR
patients with advanced colorectal cancer can not benefit from them. Therefore, the use of
PD-1 / PD-L1 monoclonal antibody in mCRC is greatly limited. Our previous research showed
that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS
mice. At the same time, a retrospective clinical study showed that patients with MSS CRC can
benefit from Sintilimab combined with Fruquintinib. Camrelizumab is PD-1 monoclonal antibody,
which has been approved for a variety of tumors. The prospective clinical trial of
Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H /
dMMR patients with mCRC.This study is aimed to explore the efficacy, safety in advanced
colorectal cancer failed to standard therapy in Chinese population.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University